Search
Barium sulfate
go.drugbank.com/drugs/DB11150ApprovedBarium sulfate is ingested by mouth or administered rectally and combined with granules of effervescent bicarbonate to enhance distension of the GI tract, allowing for enhanced gastrointestinal tract visualization
Categories: Compounds used in a research, industrial, or household settingProducts: Baricon for Suspension, Barosperse for Susp 95%Ramucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalRamucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing … In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it.
Products: CYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML, CYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50MLPegaspargase
go.drugbank.com/drugs/DB00059ApprovedInvestigationalleukemia (ALL). … [A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927]
Categories: Compounds used in a research, industrial, or household settingProducts: ONCASPAR POWDER FOR SOLUTION FOR INJECTION/INFUSION 750 U/ML, Oncaspar 750 U/ml powder for solution for injection/infusionCeftazidime
go.drugbank.com/drugs/DB00438ApprovedInvestigational[L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of
Mixtures: CEFAZIME FOR INJECTION 1 g/vialCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseMoroctocog alfa
go.drugbank.com/drugs/DB13999ApprovedMoroctocog alfa is approved by Health Canada and by the European Medicines Agency for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia … Replacement of Factor VIII is essential for the treatment of Hemophilia A, which is caused by mutations in the Factor VIII gene, leading to a functional deficiency or complete loss of protein.
Products: Xyntha 250 IU Powder and Solvent for Solution for Injection, Xyntha 1000 IU Powder and Solvent for Solution for InjectionCoagulation Factor IX (Recombinant)
go.drugbank.com/drugs/DB00100ApprovedRecombinant Factor IX is indicated for the control and prevention of bleeding episodes in adult and pediatric patients with congenital factor IX deficiency (Hemophilia B). … Factor IX complex), and is instead produced by a genetically engineered Chinese hamster ovary (CHO) cell line that secretes recombinant Factor IX into cell medium that is then processed and purified for
Products: BeneFIX Powder and Solvent for Solution for Injection 250iu/vial, BeneFIX Powder and Solvent for Solution for Injection 1000iu/vialTuroctocog alfa
go.drugbank.com/drugs/DB09109ApprovedTuroctocog alfa is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally … Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials.
Products: NovoEight 500IU Powder and Solvent for Solution for Injection, NovoEight 1000IU Powder and Solvent for Solution for InjectionAflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[L47915] All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrates and exhibit some degree of chain heterogeneity, including … [L47966,L47971] The intravitreal formulation, under the brand name EYELEA, was approved by the FDA for the treatment of retinopathy of prematurity in preterm infants in February 2023 and for the treatment
Products: Zaltrap 25mg/ml Concentrate for Solution for Infusion, ZALTRAP CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/MLFlunisolide
go.drugbank.com/drugs/DB00180ApprovedIt is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors.
Categories: Corticosteroids for Systemic Use, Drugs for Obstructive Airway DiseasesProducts: FLUNISOLIDE ALLENAlirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaProducts: PRALUENT 150 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN), PRALUENT 75 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN)